Munich, 15 July 2010. WILEX AG (ISIN DE0006614720 / WL6 / Frankfurt Stock Exchange) received a tender offer for a mandatory takeover bid by dievini Hopp BioTech Holding GmbH & Co. KG, Walldorf, Germany (dievini) late yesterday evening. The German Federal Financial Supervisory Authority (BaFin) has reviewed and approved the offer document.
dievini is obliged under section 35 para. 2 German Securities Acquisition and Takeover Act (WpÜG) to make an offer to acquire all of WILEX's bearer shares after exceeding the control threshold of 30% of the Company's voting rights on 2 June 2010. dievini now has an equity interest of 35.65% in WILEX.
The offer price is EUR 4.10 per share and exceeds the statutory minimum price of EUR 4.07. The acceptance period for the offer starts to run on 15 July 2010 and ends at midnight CET on 12 August 2010. The Executive Management Board and the Supervisory Board of WILEX AG will issue a statement regarding the mandatory offer.
The offer document will be posted solely in German on the web pages of both the prospective buyer (www.dievini.com) and WILEX AG (www.wilex.de) from 15 July 2010 onwards and made available for inspection, at no charge, by DZ BANK AG Deutsche Zentral-Genossenschaftsbank, Frankfurt/Main, Abteilung F/GTKS, Platz der Republik, 60265 Frankfurt/Main, Germany, Fax: + 49 (0) 69 7447 3685 ("DZ BANK").
About WILEX AG
WILEX AG is a biopharmaceutical company based in Munich and is listed at the Frankfurt Stock Exchange at the Regulated Market / Prime Standard. WILEX's mission is to develop drugs with a low side effect profile and targeted treatment of different types of cancer as well as diagnostic agents for specific detection of tumours. The Company's product candidates are based on antibodies and small molecules. WILEX has an attractive product pipeline which includes both drug and diagnostic candidates: A pivotal Phase III study with REDECTANE® has been completed and positive data published. RENCAREX® is undergoing a Phase III registration trial. Positive MESUPRON® Phase II data in the indication pancreatic cancer have been published and another Phase II trial in breast cancer is ongoing. The MEK inhibitor WX-554 has completed a Phase I trial. A further oncology project (PI3K inhibitor WX-037) is in preclinical development and three antibody programmes are in research. WILEX aims within a few years to be able to finance its research and development programmes from its operating cash flow. Website: http://www.WILEX.com, ISIN DE0006614720 / WKN 661472 / Symbol WL6